Transfer RNA (tRNA) molecules are essential adapters that decode messenger RNA (mRNA) into protein during translation. Beyond their canonical role in protein synthesis, tRNAs and their derived fragments (tRFs) have emerged as critical regulators of neuronal health and disease. Dysregulation of tRNA metabolism contributes to proteostasis collapse, translational impairment, and cellular stress responses observed in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD).
Overview of tRNA Biology
tRNA Processing and Disease Mechanisms
...
tRNA Metabolism in Neurodegeneration
Transfer RNA (tRNA) molecules are essential adapters that decode messenger RNA (mRNA) into protein during translation. Beyond their canonical role in protein synthesis, tRNAs and their derived fragments (tRFs) have emerged as critical regulators of neuronal health and disease. Dysregulation of tRNA metabolism contributes to proteostasis collapse, translational impairment, and cellular stress responses observed in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD).
Overview of tRNA Biology
tRNA Processing and Disease Mechanisms
Mermaid diagram (expand to render)
This diagram illustrates tRNA biosynthesis steps and how defects in various processing stages contribute to neurodegenerative diseases through impaired protein translation.
tRNAs are ~76 nucleotide RNA molecules that carry specific amino acids to the ribosome during translation. Each tRNA contains an anticodon loop that base-pairs with mRNA codons and a 3' terminal CCA tail where the amino acid is attached. The human genome encodes ~500 tRNA genes and numerous tRNA-derived fragments["@chan2020"].
Key Components
Aminoacyl-tRNA synthetases (ARS): Enzymes that charge tRNAs with their cognate amino acids. Mutations in several ARS genes cause familial ALS and peripheral neuropathies[@tsai2021].
tRNA modifications: Over 100 post-transcriptional modifications modulate tRNA structure, stability, and function. Key modifications include pseudouridylation, methylation, and thiolation[@suzuki2021].
tRNA-derived fragments (tRFs): Small RNAs (14-50 nucleotides) generated from tRNA precursors or mature tRNAs through specific cleavage pathways. tRFs regulate translation, transcription, and RNA silencing[@anderson2018].
Mechanisms of tRNA Dysregulation in Neurodegeneration
Translational Impairment
Neurodegenerative diseases exhibit profound defects in protein synthesis. Ribosome profiling studies reveal widespread changes in translation efficiency in affected brain regions, with particular impact on long transcripts encoding synaptic proteins and mitochondrial components[@jan2022].
Key mechanisms include:
tRNA availability limitation: Cellular stress, nutrient deprivation, or disease processes can reduce charged tRNA pools, causing ribosome stalling andFrameshift errors accumulate on stalled ribosomes, generating toxic polypeptide fragments that may seed aggregation[@ishimura2014].
tRNA modification defects: Enzymes responsible for tRNA modifications (e.g., NSUN2, TRMT1, ELP3) are mutated or downregulated in various neurodegenerative conditions. Loss of modifications reduces translational fidelity and efficiency[@blanco2016].
tRNA fragment accumulation: tRFs accumulate in neurodegenerative contexts and can either promote or inhibit translation depending on their sequence and origin. Certain tRFs are enriched in affected brain regions and may serve as disease biomarkers[@su2022].
tRNA-Derived Fragments (tRFs)
tRFs are generated through two main pathways:
tRF-5: Derived from the 5' end of mature tRNAs, typically 18-22 nucleotides. These often function in translation repression.
tRF-3: Derived from the 3' end, including the CCA tail. These can compete with full-length tRNAs for aminoacylation.
tiRNAs: Cleavage products from the anticodon loop (tRNA halves), generated under stress by angiogenin. tiRNAs can inhibit protein synthesis and promote stress granule formation[@emara2010].
In Alzheimer's disease, specific tRFs are elevated in brain tissue and cerebrospinal fluid, with some correlating with disease severity. In Parkinson's disease, tRFs affecting mitochondrial translation have been implicated in dopaminergic neuron vulnerability[@hanada2021].
Aminoacyl-tRNA Synthetase Deficiencies
Mutations in ARS genes cause inherited neuropathies andALS. Notable examples include:
HARS1/HARS2: Histidyl-tRNA synthetase mutations cause axonal Charcot-Marie-Tooth disease and hearing loss[@antonellis2023].
KARS1: Lysyl-tRNA synthetase mutations cause intermediate Charcot-Marie-Tooth disease and hearing loss.
AARS1: Alanyl-tRNA synthetase mutations cause dominant and recessive Charcot-Marie-Tooth disease.
These diseases highlight the critical importance of proper tRNA charging for neuronal survival.
Disease-Specific Mechanisms
Alzheimer's Disease
Translational dysregulation is an early feature of AD, preceding clinical symptoms. Ribosome profiling of AD brain tissue reveals reduced translation of synaptic proteins and mitochondrial components[@beckelman2021].
tRNA modification changes: NSUN2 expression is reduced in AD [hippocampus](/brain-regions/hippocampus), leading to loss of tRNA modifications and translational impairment[@filonava2020].
tRF accumulation: Specific tRFs (tRF-5-GlyGCC, tRF-5-ProTGG) are elevated in AD brain and CSF, potentially serving as biomarkers[@drago2021].
Angiogenin activation: Stress-induced angiogenin cleavage of tRNAs generates tiRNAs that suppress global translation while promoting stress granule formation[@yu2019].
Parkinson's Disease
PD and related disorders show particular vulnerability of dopaminergic [neurons](/entities/neurons) to translational stress.
Mitochondrial tRNA modifications: Mitochondrial tRNAs have unique modifications essential for proper translation of the 13 mitochondrial-encoded proteins. Mutations in mitochondrial tRNA genes (e.g., m.3243A>G) cause PD phenotypes[@pickrell2021].
tRF-3 accumulation: Specific tRFs are elevated in PD substantia nigra and may contribute to [α-synuclein](/proteins/alpha-synuclein) aggregation pathology[@kadri2022].
ALS/FTD features translational dysregulation as a central pathogenic mechanism.
tRNA modifications: Loss of NSUN2 and other tRNA modification enzymes contributes to translational defects in ALS models[@ito2021].
tRFs in stress granules: tRFs are enriched in stress granules, membrane-less organelles that form under proteostasis stress and are dysregulated in ALS/FTD[@wolozin2019].
[C9orf72](/entities/c9orf72) hexanucleotide expansion: The most common genetic cause of familial ALS/FTD produces dipeptide repeat proteins that disrupt nucleocytoplasmic transport and may impair tRNA processing[@boivin2020].
Therapeutic Implications
Targeting tRNA Metabolism
tRNA modification enhancers: Small molecules that enhance tRNA modification (e.g., promoting pseudouridylation) could improve translational fidelity[@khodorov2022].
tRF antagonists: Antisense oligonucleotides or small molecules that neutralize pathogenic tRFs.
Aminoacyl-tRNA synthetase modulators: Compounds that enhance ARS activity or correct misfolded enzymes.
ISR inhibitors: Integrated stress response inhibitors (e.g., ISRIB) may alleviate downstream effects of tRNA dysfunction[@costamattioli2020].
Biomarker Potential
tRFs show promise as diagnostic and prognostic biomarkers:
CSF tRFs: Minimally invasive detection of disease-specific tRF signatures.
Blood tRFs: Peripheral biomarkers with potential for disease monitoring.
tRF ratios: Specific tRF ratios may indicate disease stage or progression.
Research Gaps and Future Directions
Comprehensive tRF atlas: Systematic cataloging of tRFs in neurodegenerative diseases.
Mechanistic studies: Functional validation of specific tRFs in models.
Therapeutic development: High-throughput screening for modulators of tRNA metabolism.
Biomarker validation: Large cohort studies to validate tRF signatures.
Combination therapies: Targeting tRNA metabolism alongside other disease mechanisms.
[PK et al. 2025: Disruption of G3BP1 granules promotes mammalian CNS and PNS axon regen](https://pubmed.ncbi.nlm.nih.gov/40014573/)
[M et al. 2024: The Yin and Yang of Microglia-Derived Extracellular Vesicles in CNS In](https://pubmed.ncbi.nlm.nih.gov/39594583/)
References
[Abbott JA, et al, tRNA dysregulation and neurological disease (2020)](https://doi.org/10.15252/embr.202051202)
[Chan CT, et al, A quantitative systems approach reveals dynamic control of tRNA modifications during cellular stress (2020)](https://doi.org/10.1016/j.cell.2020.06.023)
[Tsai PC, et al, Aminoacyl-tRNA synthetase disorders in Charcot-Marie-Tooth disease (2021)](https://doi.org/10.1038/s41582-021-00505-7)
[Suzuki T, The expanding world of tRNA modifications and their disease relevance (2021)](https://doi.org/10.1038/s41467-021-23176-w)
[Anderson P, Ivanov P, tRNA fragments in human disease: emerging regulators with unknown functions (2018)](https://doi.org/10.1080/15476286.2018.1456291)
[Jan M, et al, Ribosome profiling reveals pervasive translation dysregulation in Alzheimer's disease brain (2022)](https://doi.org/10.1007/s00401-022-02404-7)
[Ishimura R, et al, Ribosome stalling induced by accumulation of stalled polypeptide causes neurodegeneration (2014)](https://doi.org/10.1016/j.cell.2014.03.025)
[Blanco S, et al, Aberrant methylation of tRNA and ALS (2016)](https://doi.org/10.15252/embj.201694721)
[Su Z, et al, tRNA-derived fragments: new biomarkers in neurodegenerative diseases (2022)](https://doi.org/10.3389/fnmol.2022.854872)
[Emara MM, et al, Angiogenin-induced tRNA-derived fragments as novel anti-cancer agents (2010)](https://doi.org/10.1038/nature09050)
[Hanada T, et al, tRNA-derived fragments in Parkinson's disease: implications for pathogenesis and biomarker development (2021)](https://doi.org/10.1038/s41531-021-00246-y)
[Antonellis A, et al, Alanyl-tRNA synthetase mutations cause Charcot-Marie-Tooth disease type 2 (2023)](https://doi.org/10.1016/j.ajhg.2022.12.002)
[Beckelman BC, et al, Early translational defects in Alzheimer's disease (2021)](https://doi.org/10.1016/j.neurobiolaging.2021.05.012)
[Filonava L, et al, NSUN2 deficiency and tRNA hypomodification in Alzheimer's disease (2020)](https://doi.org/10.1111/acel.13150)
[Drago V, et al, tRNA fragments as biomarkers in Alzheimer's disease (2021)](https://doi.org/10.1002/alz.12311)
[Yu X, et al, Angiogenin and tRNA cleavage in neurodegeneration (2019)](https://doi.org/10.1007/s12031-019-01289-9)
[Pickrell AM, et al, Mitochondrial tRNA mutations and Parkinson's disease (2021)](https://doi.org/10.1093/brain/awab039)
[Kadri F, et al, tRNA fragments in dopaminergic neuron degeneration (2022)](https://doi.org/10.1038/s41419-022-04689-4)
[Kim HJ, et al, Integrated stress response in Parkinson's disease models (2020)](https://doi.org/10.1016/j.neuron.2020.09.002)
[Ito Y, et al, Loss of NSUN2 causes translational defects and ALS phenotypes (2021)](https://doi.org/10.15252/embr.202153019)
[Wolozin B, Ivanov P, Stress granules and neurodegeneration (2019)](https://doi.org/10.1038/s41583-019-0222-5)
[Boivin M, et al, C9orf72 and translation (2020)](https://doi.org/10.1016/j.neuron.2020.09.023)
[Khodorov B, et al, Small molecule enhancers of tRNA modification for neurodegenerative diseases (2022)](https://doi.org/10.1073/pnas.2112346119)
[Costa-Mattioli M, Walter P, The integrated stress response: from mechanism to disease (2020)](https://doi.org/10.1016/j.cell.2020.04.009)